Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Denmark: These 49 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Denmark: These 49 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Denmark?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Denmark Patent 2,101,740

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Denmark?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Denmark Patent 2,086,940

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Denmark?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Denmark Patent 2,101,777

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Denmark?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Denmark Patent 2,091,940

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Denmark?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Denmark Patent 3,176,159

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in Denmark?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Denmark Patent 1,968,601

VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Denmark?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Denmark Patent 2,120,963

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Denmark?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Denmark Patent 1,973,545

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Denmark?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Denmark Patent 2,495,016

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Denmark?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Denmark Patent 2,107,905

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can MACRILEN (macimorelin acetate) generic drug versions launch in Denmark?

Generic name: macimorelin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 19, 2027
Generic Entry Controlled by: Denmark Patent 1,984,744

MACRILEN is a drug marketed by Aeterna Zentaris. There is one patent protecting this drug.

See drug price trends for MACRILEN.

The generic ingredient in MACRILEN is macimorelin acetate. Additional details are available on the macimorelin acetate profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Denmark?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Denmark Patent 2,079,445

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Denmark?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Denmark Patent 2,079,445

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Denmark?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Denmark Patent 2,380,874

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can INLYTA (axitinib) generic drug versions launch in Denmark?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Denmark Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Denmark?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Denmark Patent 2,007,756

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Denmark?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Denmark Patent 2,674,428

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Denmark?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Denmark Patent 3,091,011

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Denmark?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Denmark Patent 2,135,199

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in Denmark?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Denmark Patent 2,023,902

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Denmark?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Denmark Patent 2,152,237

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Denmark?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Denmark Patent 3,090,730

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Denmark?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Denmark Patent 4,218,732

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Denmark?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Denmark Patent 2,155,696

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Denmark?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Denmark Patent 2,164,473

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Denmark?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,164,467

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Denmark?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,500,014

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Denmark?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,164,467

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Denmark?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Denmark Patent 2,500,014

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Denmark?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Denmark Patent 2,173,752

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Denmark?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Denmark Patent 2,740,731

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Denmark?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Denmark Patent 3,070,090

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in Denmark?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Denmark Patent 2,484,346

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in Denmark?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Denmark Patent 2,719,378

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Denmark?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Denmark Patent 2,170,050

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Denmark?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Denmark Patent 2,069,374

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Denmark?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Denmark Patent 2,069,374

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Denmark?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Denmark Patent 2,069,374

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Denmark?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Denmark Patent 2,081,921

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Denmark?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,046,318

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Denmark?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,450,035

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Denmark?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,046,318

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Denmark?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,450,035

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Denmark?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Denmark Patent 2,164,844

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can RASUVO (methotrexate) generic drug versions launch in Denmark?

Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Denmark Patent 2,046,332

Drug Price Trends for RASUVO
RASUVO is a drug marketed by Medexus. There is one patent protecting this drug. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. Additional details are available on the methotrexate profile page.

When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch in Denmark?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Denmark Patent 2,016,940

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch in Denmark?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Denmark Patent 2,016,940

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Denmark?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Denmark Patent 2,173,891

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Denmark?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Denmark Patent 2,503,004

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Denmark?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Denmark Patent 2,503,005

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Denmark?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Denmark Patent 2,966,175

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Denmark?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Denmark Patent 3,042,901

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Denmark?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Denmark Patent 2,187,965

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Denmark?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Denmark Patent 2,182,988

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Denmark?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Denmark Patent 2,207,526

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can MYRBETRIQ (mirabegron) generic drug versions launch in Denmark?

Generic name: mirabegron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2027
Generic Entry Controlled by: Denmark Patent 2,216,021

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. Additional details are available on the mirabegron profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Denmark?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Denmark Patent 2,222,285

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Denmark?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Denmark Patent 3,143,992

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Denmark?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Denmark Patent 3,492,069

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Denmark?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Denmark Patent 3,895,699

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Denmark?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Denmark Patent 2,091,918

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Denmark?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Denmark Patent 2,217,577

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Denmark?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Denmark Patent 2,217,577

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Denmark?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Denmark Patent 2,096,919

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Denmark?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Denmark Patent 2,225,230

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Denmark?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Denmark Patent 3,170,818

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Denmark?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Denmark Patent 2,234,617

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can ONPATTRO (patisiran sodium) generic drug versions launch in Denmark?

Generic name: patisiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 27, 2027
Generic Entry Controlled by: Denmark Patent 2,279,254

ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering ONPATTRO

See drug price trends for ONPATTRO.

The generic ingredient in ONPATTRO is patisiran sodium. Additional details are available on the patisiran sodium profile page.

Denmark Branded and Generic Drug Markets: Regulatory Assessment, Market Access, and Commercial Opportunities

Last updated: October 19, 2026

Denmark is a high-income, tightly regulated pharmaceutical market with strong generic substitution, centralized hospital procurement, extensive public reimbursement, and rapid uptake of biosimilars. Generic manufacturers compete primarily on price, supply reliability, and pharmacy distribution. Branded products retain commercial value in patented indications, specialty medicines, hospital therapies, and products with limited substitution.

The main opportunities are EU-wide marketing authorization, hospital tender participation, biosimilar launches, parallel importation, specialty medicines, and lifecycle management. The main challenges are low prices, frequent price competition, centralized purchasing, strict reimbursement controls, small population size, and limited commercial leverage after patent expiry.

How large is the Danish branded and generic drug market?

Denmark has approximately 6 million inhabitants and a mature pharmaceutical distribution system. Prescription medicines are supplied through community pharmacies, hospitals, specialist clinics, and online pharmacy channels. Public expenditure dominates reimbursed prescription and hospital drug spending.

The market has two distinct commercial segments:

Segment Main buyer or payer Competitive basis Typical market access route
Community prescription medicines Patients, municipalities, Danish regions, public reimbursement Pharmacy price, reimbursement status, substitution, supply Marketing authorization, pharmacy distribution, reimbursement application
Hospital medicines Five Danish regions through Amgros Tender price, clinical value, supply security, contract terms Marketing authorization, hospital assessment, Amgros tender
Over-the-counter medicines Consumers and pharmacies Brand, price, pharmacy placement, consumer demand Marketing authorization and nonprescription classification
Specialty and biologic medicines Hospitals, regions, specialist prescribers Clinical evidence, budget impact, treatment protocols EMA or national authorization, procurement, clinical guidance

The Danish market is small in volume relative to Germany, France, Italy, or the United Kingdom. Its commercial importance comes from predictable regulation, high healthcare coverage, strong data quality, and its role as a reference market for Nordic pricing and procurement decisions.

The market is not divided into a simple branded-versus-generic structure. It includes originator brands, authorized generics, branded generics, parallel imports, biosimilars, hospital tender products, and products supplied under special reimbursement arrangements.

What is the role of generic medicines in Denmark?

Generic medicines have a dominant position in off-patent community prescribing. Danish pharmacies must generally substitute a prescribed medicine with the least expensive interchangeable product unless the prescriber or patient has a legally recognized reason to prevent substitution.

The Danish Medicines Agency determines substitution groups and publishes rules governing interchangeable products. Pharmacies normally dispense the lowest-priced medicine within the relevant group. Patients can request the prescribed product, but they may have to pay the price difference.

Price competition is intensified by Denmark’s periodic pharmacy pricing system. Prices for many reimbursed prescription medicines are submitted and updated at regular intervals, commonly every two weeks. A generic company therefore can lose volume rapidly if its price is not competitive or if it cannot maintain supply.

What factors determine generic market share?

Generic performance depends on:

  • Inclusion in a substitution group.
  • Lowest or near-lowest pharmacy purchase price.
  • Reliable deliveries to wholesalers and pharmacies.
  • Reimbursement eligibility.
  • A competitive launch immediately after loss of exclusivity.
  • Recognition by prescribers, pharmacies, and hospital purchasers.
  • Ability to manage frequent price changes.
  • Compliance with serialization, pharmacovigilance, and packaging requirements.

Generic entry is strongest where the active ingredient has several approved suppliers and the dosage form is technically straightforward. Competition is more limited for sterile injectables, modified-release products, complex inhalers, transdermal systems, and products requiring specialized manufacturing.

How are branded medicines positioned in Denmark?

Originator brands retain the strongest position in patented medicines, biologics, rare disease products, hospital therapies, and products with limited generic or biosimilar competition. Brand loyalty is weaker in routine primary-care prescribing because substitution and reimbursement rules shift purchasing decisions toward price.

Branded products compete through:

  • Patent and regulatory exclusivity.
  • Clinical differentiation.
  • Specialist prescribing.
  • Hospital treatment protocols.
  • Patient support and adherence programs.
  • Formulation or delivery-system improvements.
  • Evidence supporting reduced hospitalization or total treatment cost.
  • Contracting with hospitals and regions.
  • Additional indications protected by method-of-use patents.

A branded product can lose substantial volume after generic entry even when the originator remains reimbursed. The loss is usually fastest when the product is easily substitutable and several suppliers enter simultaneously.

What is the Danish reimbursement system for prescription medicines?

Denmark uses a tiered reimbursement system for eligible outpatient prescription medicines. Reimbursement is generally linked to the patient’s cumulative annual medicine expenditure, meaning public support increases as eligible spending rises. The exact thresholds and percentages are adjusted periodically.

The principal reimbursement categories include:

  • General reimbursement for medicines meeting statutory criteria.
  • Conditional reimbursement linked to defined diagnoses or prescribing conditions.
  • Individual reimbursement granted for a specific patient.
  • Reimbursement for terminal illness or other special circumstances.
  • Municipal or regional support in selected treatment settings.

The Danish Medicines Agency evaluates whether a medicine qualifies for general reimbursement. The assessment considers treatment value, disease severity, target population, and expected expenditure. A product may receive reimbursement for all approved use or only for restricted indications.

For branded medicines, reimbursement access can be commercially more important than the marketing authorization itself. A product without reimbursement may remain legally marketable but have limited prescription demand.

How does hospital procurement work in Denmark?

Danish hospital procurement is highly centralized. The five Danish regions purchase medicines through Amgros, the national procurement company owned by the regions. Amgros conducts tenders for hospital medicines and negotiates framework agreements with suppliers.

The procurement process can determine which product hospitals use even when multiple medicines are therapeutically interchangeable. Tender awards often reflect:

  • Net price.
  • Clinical equivalence.
  • Supply reliability.
  • Delivery terms.
  • Contract duration.
  • Packaging and logistics.
  • Environmental requirements.
  • Ability to support national or regional implementation.

For biologics, hospitals can establish treatment guidelines that favor a lower-cost biosimilar or switch stable patients when clinically acceptable. A biosimilar may therefore gain rapid market share after tender success.

The commercial consequence is a sharp distinction between community and hospital markets. Community products are exposed to pharmacy substitution and short price cycles. Hospital products are exposed to concentrated buyers and tender-driven volume commitments.

What regulatory pathways are available for pharmaceutical companies?

Companies can access Denmark through EU regulatory procedures or, in limited circumstances, national procedures.

Regulatory route Use case Decision-maker
Centralized procedure Most innovative medicines, biologics, oncology products, advanced therapies, and products required to use the EU route European Commission following EMA opinion
Decentralized procedure Generic, hybrid, or other products not previously authorized in an EU member state Reference and concerned member states
Mutual recognition procedure Expansion of an existing national authorization to additional EU countries National competent authorities
National procedure Products intended only for Denmark where EU rules permit national authorization Danish Medicines Agency

The Danish Medicines Agency is responsible for national implementation, pharmacovigilance, inspections, clinical trial oversight, and certain reimbursement and substitution decisions. Products authorized centrally by the European Commission still require Danish commercial, pricing, reimbursement, packaging, and distribution compliance.

What are the language and packaging requirements?

Medicines supplied in Denmark generally require Danish-language product information and packaging elements, subject to applicable EU exceptions. Companies must address:

  • Danish package leaflets.
  • Product labeling.
  • Pharmacovigilance contacts.
  • National reimbursement and substitution data.
  • Serialisation and anti-tampering requirements.
  • Wholesale distribution authorization.
  • Temperature-controlled logistics.
  • Electronic product information and reporting obligations.

A centralized authorization does not remove the need for Denmark-specific launch preparation.

What patent and exclusivity rules affect branded and generic entry?

Denmark follows EU pharmaceutical and patent rules. Generic entry is usually constrained by the originator’s basic patent, supplementary protection certificate, regulatory exclusivity, formulation patents, and method-of-use patents.

Key protection mechanisms include:

Protection Typical effect
Basic compound patent Protects the active ingredient, subject to national or unitary coverage
Supplementary protection certificate Extends protection for eligible products after patent expiry, usually by up to five years, with a possible pediatric extension
Regulatory data protection Restricts reliance on the originator’s dossier during the applicable EU period
Marketing protection Can delay generic or biosimilar commercialization after authorization
Formulation patent May protect a particular composition, excipient system, release profile, or dosage form
Method-of-use patent May cover a patented indication or treatment method
Manufacturing patent May cover a process, intermediate, crystal form, or purification method

Denmark is covered by the Unified Patent Court system and the Unitary Patent regime introduced in 2023. Patent holders can pursue unitary protection across participating states, while national Danish patents and European patents validated in Denmark remain relevant.

Does Denmark have an Orange Book or a Paragraph IV system?

Denmark does not have a direct equivalent to the U.S. FDA Orange Book. Companies must instead assess:

  • Danish patent registers.
  • European Patent Office records.
  • Unitary Patent and Unified Patent Court records.
  • SPC databases.
  • EMA and European Commission authorization data.
  • Danish Medicines Agency product and substitution information.
  • National court decisions and commercial litigation records.

Denmark also does not operate the U.S. Hatch-Waxman Paragraph IV process. Generic and originator disputes are handled through European patent opposition, revocation, infringement, interim injunction, and national litigation mechanisms.

A Danish generic applicant may challenge patent validity or non-infringement before launch. The strategic analysis must cover Denmark and other relevant European jurisdictions because a European patent, unitary patent, or UPC action may affect several markets at once.

When does a Danish generic lose exclusivity risk?

Generic entry risk generally rises when:

  1. The active-ingredient patent expires.
  2. Any SPC expires or is found invalid.
  3. Regulatory data and market protection periods end.
  4. Major European generic companies file or obtain approval.
  5. Hospital tenders open for the active ingredient.
  6. Biosimilar competitors complete comparability and authorization requirements.
  7. Formulation or indication patents fail to block the intended product.

The key commercial date is not always the basic patent expiry date. A later SPC, pediatric extension, unitary patent, or enforceable formulation patent may control the practical launch date.

How strong are formulation, method-of-use, and manufacturing patents in Denmark?

Secondary patents can materially delay or complicate generic entry, but their value depends on claim scope and the product’s actual design.

Formulation patents

Formulation patents are most relevant for:

  • Extended-release tablets.
  • Fixed-dose combinations.
  • Injectable products.
  • Long-acting formulations.
  • Inhaled medicines.
  • Ophthalmic products.
  • Device-linked delivery systems.

A generic company may avoid infringement by using a different excipient, release mechanism, concentration, or manufacturing process. The strength of the patent depends on whether the claims cover the commercial product broadly or only a narrow technical configuration.

Method-of-use patents

Method-of-use patents can protect a new indication, patient subgroup, dosing schedule, or treatment combination. They may be commercially relevant where the patented indication represents a large share of demand.

Generic companies may seek a label that omits the protected indication, although prescribing and dispensing practices can make enforcement complex. Originators must also rely on regulatory, contracting, and clinical communication controls to reduce off-label substitution risk.

Manufacturing and process patents

Manufacturing patents are important for complex active pharmaceutical ingredients, biologics, peptides, sterile products, and highly purified intermediates. They can create practical barriers even if the composition patent has expired.

These rights are most effective when the process is difficult to design around or when the product’s quality profile depends on the protected process.

What is the biosimilar opportunity in Denmark?

Denmark is one of Europe’s more developed biosimilar markets. Hospitals have used procurement and clinical guidance to promote biosimilar competition in areas such as oncology, rheumatology, endocrinology, and supportive care.

Biosimilar opportunities are strongest where:

  • The reference biologic has high hospital expenditure.
  • Multiple suppliers can manufacture at scale.
  • The product is administered in hospitals.
  • Clinical switching protocols are established.
  • Tender volumes are sufficiently large.
  • The reference product’s SPC and regulatory exclusivity have expired.

Biosimilar companies face a different market-access model from generic companies. Approval requires a comparability package under EMA rules rather than a conventional small-molecule bioequivalence submission. Commercial success depends heavily on tender economics, manufacturing consistency, pharmacovigilance, and physician confidence.

Interchangeability is not determined solely by EMA authorization. National decisions and clinical practice influence switching and substitution. Companies should not assume that an EU biosimilar approval creates automatic pharmacy-level substitution in Denmark.

Which companies are likely to compete in the Danish market?

The competitive landscape includes four groups.

Danish and Nordic companies

Novo Nordisk is the most commercially significant Danish pharmaceutical company, particularly in diabetes, obesity, and related chronic diseases. Lundbeck is important in central nervous system medicines. Leo Pharma has a strong dermatology presence. These companies compete mainly through innovative and specialty products rather than traditional generic volume.

Global originators

Large multinational companies maintain positions in oncology, immunology, cardiovascular disease, respiratory medicine, vaccines, rare diseases, and hospital products. Their primary defenses are patents, clinical evidence, specialist access, and procurement contracts.

Generic manufacturers

European and global generic companies compete through low prices, broad product portfolios, regulatory scale, and supply infrastructure. Teva, Viatris, Sandoz, STADA, Zentiva, and regional suppliers have historically been visible across European generic markets, although product participation varies by molecule and tender.

Parallel importers and wholesalers

Parallel imports can capture significant share in established products by sourcing medicines from other European markets at lower prices. This creates additional pressure on originator and generic pricing while increasing the importance of packaging, reimbursement, and supply-chain execution.

What licensing and partnership models are available?

Denmark is generally accessed through broader European licensing arrangements rather than Denmark-only transactions. Common models include:

  • EU-wide commercialization licenses.
  • Nordic distribution agreements.
  • Co-promotion arrangements for specialty medicines.
  • Contract manufacturing and supply agreements.
  • Biosimilar development partnerships.
  • In-licensing of niche hospital products.
  • Out-licensing of Danish-originated assets.
  • Parallel-import and wholesaler agreements.
  • Co-development of complex generics and delivery systems.

For a small market, a Denmark-specific sales force may be uneconomic unless the product has high value, hospital concentration, or strong Nordic synergies. A regional Nordic agreement can reduce fixed commercial costs while preserving access to Denmark’s regulatory and procurement systems.

What litigation and settlement risks affect market entry?

The principal disputes involve patent validity, infringement, SPC entitlement, preliminary injunctions, product liability, procurement challenges, and reimbursement decisions.

Settlement agreements can control the practical date of generic or biosimilar entry. Commercial terms may include:

  • Delayed entry.
  • License-based early entry.
  • Supply arrangements.
  • Authorized generic launches.
  • Restrictions on specific indications or formulations.
  • Confidential commercial terms.

Companies must evaluate whether a settlement is compatible with EU competition law. Agreements that unnecessarily delay competition or allocate markets can attract regulatory scrutiny.

Hospital procurement decisions can also be challenged under Danish and EU public procurement rules. A supplier excluded from an Amgros tender may have remedies if the tender process breached transparency, equal treatment, or award criteria requirements.

What are the principal regulatory opportunities and challenges?

Opportunity Commercial rationale Main challenge
EU centralized authorization One authorization can support Denmark and other EU markets High evidence, compliance, and launch coordination burden
Generic substitution Fast volume uptake after loss of exclusivity Severe price competition
Biosimilars Hospital tenders can produce rapid adoption Manufacturing and tender-price pressure
Specialty medicines Higher barriers can reduce direct competition Small patient populations and reimbursement scrutiny
Hospital tenders Access to concentrated purchasing Contract loss can remove most national volume
Parallel imports Established distribution channel Margin pressure and packaging complexity
Nordic expansion Shared commercial infrastructure Different reimbursement and procurement rules
Complex generics Less crowded competition Greater development, patent, and manufacturing cost
Lifecycle management New formulations and indications can extend value Secondary patents may face validity challenges

What generic launch scenarios are most likely?

Scenario 1: Multi-supplier commodity launch

Several companies enter immediately after exclusivity ends. Pharmacy substitution directs volume toward the lowest-priced supplier. Originator share falls rapidly, while generic margins compress.

Scenario 2: Limited-supplier launch

Only one or two companies obtain approval or secure supply. Prices remain higher, but supply disruption creates material commercial risk. This is common in complex dosage forms or sterile products.

Scenario 3: Hospital-led biosimilar switch

A biosimilar wins an Amgros tender and becomes the preferred hospital product. Market share changes quickly, subject to clinical guidance and supply continuity.

Scenario 4: Patent-delayed entry

A basic patent expires, but an SPC, formulation patent, method-of-use patent, or litigation injunction delays launch. The commercial outcome depends on claim breadth and the generic’s design-around strategy.

Key Takeaways

  • Denmark is a high-access but low-price pharmaceutical market.
  • Generic substitution and frequent price competition make community products highly cost-sensitive.
  • Amgros tenders control much of the hospital market and can rapidly shift volume to low-cost suppliers.
  • Branded products retain strength in patented, specialty, biologic, and clinically differentiated categories.
  • Denmark has no U.S.-style Orange Book or Paragraph IV system.
  • Patent analysis must cover Danish rights, European patents, SPCs, Unitary Patents, and UPC proceedings.
  • Biosimilars have strong potential, particularly in hospital-administered therapies.
  • The best opportunities are complex generics, biosimilars, specialty products, hospital medicines, and Nordic licensing platforms.
  • The main risks are low net prices, concentrated purchasing, supply obligations, rapid substitution, and short commercial windows after patent expiry.

FAQs About Denmark’s Pharmaceutical Market

Is Denmark a favorable market for generic drug launches?

Yes, if the product has a clear substitution pathway, multiple distribution partners, and a reliable low-cost supply chain. The market is unfavorable for undifferentiated products with high manufacturing costs or weak pharmacy availability.

How quickly do Danish pharmacies substitute generic medicines?

Substitution generally occurs at dispensing when an interchangeable lower-priced product is available, subject to prescriber, patient, reimbursement, and regulatory exceptions. The commercial effect can be immediate after a generic enters a substitution group.

Are biosimilars automatically interchangeable in Denmark?

No. EMA authorization establishes biosimilarity, but national rules and clinical practice determine how substitution and switching operate. Hospital procurement and treatment guidelines are central to biosimilar uptake.

Can a generic company launch in Denmark before a European patent expires?

Only if the product does not infringe an enforceable right, the relevant patent is invalid or revoked, the launch is otherwise legally permitted, or the company has a license or settlement right. Denmark’s patent analysis must include European and unitary rights.

Does Denmark offer market exclusivity for orphan medicines?

Orphan medicines can receive EU orphan designation and associated regulatory incentives, including market exclusivity under EU law, subject to the applicable conditions and exceptions. Commercial access still depends on reimbursement, clinical use, and hospital or regional purchasing decisions.

References

  1. Amgros. (n.d.). Amgros: Pharmaceutical procurement for the Danish regions. https://www.amgros.dk/

  2. Danish Medicines Agency. (n.d.). Medicines and reimbursement. https://laegemiddelstyrelsen.dk/

  3. Danish Medicines Agency. (n.d.). Substitution and interchangeable medicines. https://laegemiddelstyrelsen.dk/

  4. European Commission. (n.d.). Pharmaceutical strategy and pharmaceutical legislation. https://health.ec.europa.eu/

  5. European Medicines Agency. (n.d.). Biosimilar medicines. https://www.ema.europa.eu/

  6. European Medicines Agency. (n.d.). Marketing authorisation procedures. https://www.ema.europa.eu/

  7. European Patent Office. (n.d.). Unitary Patent and Unified Patent Court. https://www.epo.org/

  8. European Union. (2004). Directive 2004/27/EC amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union.

  9. European Union. (2009). Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products. Official Journal of the European Union.

  10. European Union. (2021). Regulation (EU) 2021/2282 on health technology assessment. Official Journal of the European Union.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.